新冠灭活疫苗Ⅲ期临床试验结果
phase-3 study results of inactivated COVID-19 vaccines

关于国药集团中国生物新冠疫苗Ⅲ期临床试验中期分析结果的论文5月26日正式发表在《美国医学会杂志》上。

The inactivated vaccine, developed by a Beijing unit of Sinopharm's China National Biotech Group, has 78.1 percent efficacy against symptomatic cases of COVID-19, while the vaccine made by the group's unit in Wuhan, Hubei province, has 72.8 percent efficacy, according to the study results.
研究显示，中国生物旗下北京生物制品研究所的新冠灭活疫苗有效性为78.1%，武汉生物制品研究所的新冠灭活疫苗有效性为72.8%。